A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

  • End date
    Mar 31, 2023
  • participants needed
  • sponsor
    Seagen Inc.
Updated on 27 January 2021
stem cell transplantation
hodgkin's disease
systemic therapy
measurable disease
combination chemotherapy
progressive disease
positron emission tomography
cancer chemotherapy
diffuse large b-cell lymphoma
b-cell lymphoma
solid tumour
solid tumor
targeted therapy
t-cell lymphoma
peripheral t-cell lymphoma
brentuximab vedotin
large b-cell lymphoma
salvage therapy
stage iv non-small cell lung cancer
pd-1 inhibitor


This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas.

The study will have three parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with pembrolizumab works to treat solid tumors. Pembrolizumab is a drug that can be used to treat these types of cancer.

Condition Non-Small Cell Lung Cancer, urinary tract neoplasm, Ovarian disorder, Diffuse Large B-Cell Lymphoma, bladder cancer, bladder disorder, Breast Cancer, Ovarian Cancer, Peripheral T-Cell Lymphoma, melanoma, T-Cell Lymphoma, Diet and Nutrition, Chronic Diarrhea, Skin Wounds, Metastatic Melanoma, Chronic Shoulder Pain, Vaginal Atrophy, Adverse Effects, Drugs, Injection Port, Breast Cancer - HER2 Positive, Anal Dysplasia, Primary Immunodeficiency, Pediatric Health, Near-Sighted Corrective Surgery, Ovarian Function, Classical Hodgkin Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Peripheral Arterial Occlusive Disease, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Brain Function, Urothelial Cancer, Squamous Cell Carcinoma of Head and Neck, Gastric Carcinoma, Recurrent Respiratory Papillomatosis, Recurrent Ovarian Cancer, Razor Bumps (Pseudofolliculitis Barbae), Metastatic Triple-Negative Breast Cancer, Malignant Melanoma, Bladder Disorders, Bladder Carcinoma, Urologic Cancer, melanoma skin, melanoma skin cancer, malignant melanoma of skin, ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, carcinoma of the bladder, diffuse large cell lymphoma, diffuse large b cell lymphoma, nsclc, ovarian tumors, bladder tumor, Gastroesophageal Junction Carcinoma
Treatment Pembrolizumab, SGN-TGT, PD-(L)1 inhibitor, SEA-TGT
Clinical Study IdentifierNCT04254107
SponsorSeagen Inc.
Last Modified on27 January 2021


How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note